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Primary malignant lymphomas in the salivary glands are relatively rare. Clinical presentation is 
not characteristic and the disease is often overlooked resulting in diagnosis and treatment delays. 
Aim: To stress the importance of the diagnostic process and combined management, we present 
a series of eight patients with malignant lymphoma of the parotid who were diagnosed only after 
surgery and managed with radiation and chemotherapy. 
Methods: Retrospective series of patients with primary malignant lymphoma of the parotid gland 
managed with radiotherapy and diagnostic surgical partial resection. 
Results: After treatment completion we achieved a loco-regional control rate of 87.5%. Toxicity was 
charted according to the Common Toxicity Criteria and it was seen in six patients (75%). Six patients 
are still alive without evidence of recurrent disease in their last follow-up. 
Conclusion: Our study confirms that primary early stage Non-Hodgkin Lymphoma of the parotid 
gland is a disease with an excellent prognosis and a good local control rate, with minimal morbidity.
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INTRODUCTION
Among lymphatic tumors involving the head and 
neck, Non-Hodgkins lymphomas (NHLs) represent just 
2%-4% of them. They represent 2%-6% of the tumor-related 
mortality amongst all the head and neck lymphomas. 
Its prevalence increases with age (peak incidence at 55 
years of age) and the male/female ratio is 2:1. Generally 
surgeons do not anticipate primary NHL in the salivary 
glands pre-operatively and pathologists too find it difficult 
to give a definitive and diagnostic report based on either 
frozen section or fine needle aspiration biopsy (FNAB). 
This difficulty in pre and intra-operative diagnosis often 
results in unnecessary radical operations to the patient 
with all its associated risks involved. 
The pathophysiology of NHL is unknown. However, 
either acquired or drug-induced immunodeficiency incre-
ases the risk by 50-100 times. Some autoimmune disorders 
are increasingly recognized as risk factors for NHL. In a 
recently conducted pooled analysis of 12 case-control stu-
dies including 29,423 participants, Sjogren’s syndrome (SS) 
was found to be associated with a 1000 fold increase in the 
risk of parotid gland marginal zone lymphoma and a 6.5 
fold increase in the risk of NHL overall1. Usually NHLs arise 
from B-lymphocytes with variable grade of differentiation 
and may involve lymph-nodes (nodal origin) or structures 
having abundant lymphatic tissue (extranodal origin).
Primary parotid gland lymphoma is a small subset of 
head and neck NHL. The overall incidence is about 0.3% 
of all tumors, 2%-5% of salivary gland neoplasm and 5% 
of extranodal lymphomas2-4. In contrast to other extranodal 
locations of NHL, parotid gland involvement is more likely 
to be of low grade and the patients have a better prognosis 
than do those with other extranodal NHL5.
The treatment of primary parotid lymphoma inclu-
des radiotherapy and chemotherapy as suggested in several 
reported series. Surgical excision is advocated only as a 
diagnostic tool.
We present our results in managing eight parotid 
gland lymphomas with combined radio-chemoterapy.
MATERIAL AND METHODS
We have done a retrospective study of all the pa-
tients managed in our department for parotid gland surgery 
during a 20 years period from 1988-2008. The patients 
managed for NHL of the parotid gland were extracted and 
analyzed. Only patients who presented with a swelling 
of the parotid as their first symptom, who did not have a 
previous diagnosis of lymphoma and who later on were 
confirmed histologically post surgically as a parotid gland 
lymphoma were included in the study. The following 
patients were excluded from the study. 1) Patients who 
had lymphoma diagnosed in the past; 2) Patients who 
had simultaneous other salivary gland involvements; 3) 
Those patients who presented with other symptoms of 
lymphoma and later on diagnosed as having a parotid 
gland involvement. 
History and clinical data were recorded from the 
clinical notes. All the patients had a complete head and 
neck examination. The instrumental evaluation included: 
Computed Tomography (CT) with contrast enhancement, 
fine needle aspiration biopsy (FNAB) and/or histological 
analysis on a specimen surgically obtained. In all the cases 
a superficial parotidectomy with preservation of the facial 
nerve was done after consultation with the patients. All 
the surgically obtained specimens underwent a definitive 
histopathologic examination. All patients were staged ac-
cording to the Ann-Arbor staging system (Table 1). Staging 
consisted of a general physical examination, hematological 
screening, CT of chest, abdomen and pelvic regions and 
bone marrow biopsy. Histopathology of the specimen was 
described in accordance with Updated Kiel classification. 
After diagnosis, all the cases received radiation-therapy 
(RT) and chemotherapy (ChT). 
Table 1. Ann Arbor Staging System for Non-Hodgkin’s Lym-
phoma.
Stage Description
I Involvement of a single lymph node region or of a single 
extranodal organ or site (IE).
II Involvement of two or more lymph node regions on the 
same side of the diaphragm, or localized involvement of an 
extranodal site or organ (IIE) and one or more lymph node 
regions on the same side of the diaphragm.
III Involvement of lymph node regions on both side of the 
diaphragm, which may also be accompanied by localized 
involvement of an extranodal organ or site (IIIE) of spleen 
(IIIS) or both (IIISE).
IV Diffuse or disseminated involvement of one or more distant 
extranodal sites.
The patients received RT as conformal external 
beam radiation to the parotid bed and also neck lymph-
nodes levels I-II & III, when indicated by the stage of the 
disease. Treatment was delivered in all cases using unilat-
eral anterior and posterior wedged-pair fields using 6 MV 
photons, MLC (multi leaf collimator) collimated. The target 
volume was expanded by one cm set up margin to gener-
ate the planning target volume (PTV). We also boosted 
the RT with the help of electron beam of 9/12 MeV in six 
patients who had superficial extension of the lesion. With 
the wedged-pair technique, slight inferior angulations of 
the beams avoided an exit dose to the contralateral eye.
Only patients with a minimum follow-up of one 
year were included. Our institutional review board ap-
proved the study.
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RESULTS
Among 346 patients undergoing parotid gland sur-
gery during the last 20 years, 11 patients had a diagnosis 
of parotid gland NHL. The first patient with diagnosis of 
NHL was recorded in 1995. The mean age was 60 years 
(range 45-80 years). Male/female ratio was 2:1. Three out 
of 11 NHL patients were excluded from the retrospective 
review as they had a previous diagnosis of lymphoma 
within the past three years.
All eight patients complained of a parotid gland 
swelling and in two patients there was bilateral enlarge-
ment of the parotid. Head and neck examination did not 
reveal any neck node enlargement in any of the patients. 
Imaging studies showed, in all cases, a well demarcated 
increase in the volume of the parotid without any signs of 
enhancement or invasion of the surrounding tissue. The 
FNAB, obtained in seven patients, were all negatives for 
malignant lymphatic lesion. In two cases it was indicative 
of Warthin’s tumor, in another two cases it suggested a 
benign lymphoepithelial lesion; and in the remaining three 
cases it only gave an inconclusive result. One patient 
did not have an FNAB done. The diagnosis of NHL in all 
patients was established after definitive histopathologic 
examination of the resected surgical specimen. In two pa-
tients with bilateral swelling the operation was done on the 
side with bigger mass for patients discomfort and with the 
purpose of definitive diagnosis. Five patients had follicular 
B cell lymphoma with predominantly small-cleaved cell 
and the remaining three had a diagnosis of diffuse large 
cell lymphoma. After staging tests: five patients were in 
stage I and three patients were in stage II. 
After diagnosis, all patients were treated with RT 
and ChT with CHOP or R-CHOP protocols administered 
at an interval of two weeks (cyclophosphamide 750 mg/
m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, pred-
nisone 100 mg for 5 days every 14 days). Rituximab was 
administered in four cases diagnosed after 2006, but no 
differences in outcomes were noted, probably due to low 
number of cases. Patients with NHL stage I underwent 
three cycles of chemotherapy, while those with stage II 
had three additional cycles. All patients received conformal 
external beam RT to the parotid bed, the three patients 
with stage II disease received irradiation to the neck up to 
level III group of lymph nodes. Median dose delivered was 
38,4 Gy (range 36,8-40 Gy) at 1.8 to 2.0 Gy per fraction. 
Tolerance of the patient to the radiation dosage decided 
the final RT dosage delivered. 
Median follow-up was two years (range one to four 
years). After RT a regional and local control, defined as no 
evidence of recurrent disease within the head and neck 
and the treated fields respectively, was obtained in 7/8 
patients (87.5%), one patient (12.5%) in which no electron 
beam boost was given, presented with local recurrence 
after six months. Toxicity was retrospectively scored ac-
cording to the Common Toxicity Criteria v. 2.0 (CTC v. 
2.0)6: six patients (75%) had grade I mucositis and two 
patients grade I dysphagia. (Table 2 and 3) None of the 
seven recurrence free patients had palpable or detectable 
residual disease in the last follow-up. Six patients are 
surviving and are disease free at their last follow-up. One 
patient with recurrent disease died after eight months from 
recurrence. One patient died of other causes not related to 
the lymphatic disease. He died after two years following 
his treatment and was disease free at his last follow up.
Table 2. Dysphagia pharyngeal related to radiation CTC v. 2.0.
Grade Description
0 None.
1 Mild dysphagia, but can eat regular diet.
2 Dysphagia, requiring predominantly pureed, soft, or liquid 
diet.
3 Dysphagia, requiring feeding tube, IV hydration or hype-
ralimentation.
4 Complete obstruction (cannot swallow saliva); ulceration 
with bleeding not induced by minor trauma or abrasion or 
perforation.
Table 3. Mucositis due to radiation CTC v. 2.0.
Grade Description
0 None
1 erythema of the mucosa
2 patchy pseudomembranous reaction (patches generally 
<1.5 cm in diameter and noncontiguous)
3 confluent pseudomembranous reaction (contiguous pa-
tches generally >1.5 cm in diameter)
4 necrosis or deep ulceration; may include bleeding not 
induced by minor trauma or abrasion
DISCUSSION
Majority of extranodal lymphomas of the head and 
neck are NHL and in 4%-5% of cases the parotid gland is 
involved3,7. Primary parotid gland NHL represents 1%-4% 
of all parotid tumors. These numbers, however, cannot 
indicate the true prevalence of the disease8-10. The true 
prevalence of such disease is not quite obtained because 
of poor consistency of the series available. Reports present 
in the literature are old and in the last decade there were 
few series describing such disease. 
Another cause of confusion in literature about the 
true incidence and then the real prognosis is the inadequa-
te staging. Such lack of patients examination data is more 
evident in the earlier cases described due to the limited 
availability of imaging and technology at that point of time 
which in today’s day and age is considered as obsolete. 
As reported by Lipton et al in 1971, as many as 35% of 
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patients presenting with NHL apparently confined to the 
head and neck region were found to have intra-abdominal 
disease after adequate staging11.
There is a debate in the scientific literature about 
the true origin of lymphomas within the parotid gland. 
Batsakis assessed that the propensity of parotid gland 
to be involved by NHL is related to the anatomy of the 
gland, rich in lymph nodes and lymphoid tissue12. Non-
Hodgkins lymphoma of the parotid gland may be classified 
as extranodal if the origin is from the mucosa associated 
lymphoid tissue (MALT) or nodal if the true origin is from 
lymph node within the gland. The lesions, in the opinion 
of some authors, arise from the lymph nodes associated 
with the gland and then the gland tissue around the lesion 
is involved secondarily. This theory makes it difficult to 
establish the true origin of the disease12. 
There are also other workers in the field who sug-
gests that, salivary glands do not normally contain MALT 
but may acquire it as a result of an autoimmune inflam-
matory disorder like Sjogren’s syndrome (SS)13. However, 
the true origin of NHL in the parotid gland is actually 
without much relevance because the treatment, till now, 
is not influenced by such detail10. We too believe in this 
viewpoint. It is generally considered that the great number 
of cases presenting with a stage I disease have a MALT 
disease and the clinical course is indolent requiring a less 
aggressive treatment14. In our current series though, we 
didn’t find MALT lymphoma patients, eventhough we had 
cases identified as stage I disease. None of our patients 
had SS either again supporting the suggestion that MALT 
lymphoma is more likely to be seen in patients with SS.
Although considered insufficient by some authors15, 
Hyman & Wolff16 have suggested some criteria to consider 
a lesion as primary parotid gland lymphoma: 1. Involve-
ment of the gland should be the first clinical manifestation 
of the disease; 2. Histologically, the disease should involve 
the gland parenchyma and not adjacent lymph nodes or 
soft tissue alone; 3. There should be confirmation of the 
malignant nature of the lymphoid infiltrate. We adopted 
these criteria to consider as primary NHL a lymphatic 
malignancy involving the parotid glands.
Diagnosis of parotid lymphoma is often not easy 
when a new parotid gland mass is evaluated. Clinical pre-
sentation is indistinguishable from other benign parotid 
swellings, but there is some clinical and historical features 
that should make the physician consider lymphoma as 
possible etiology of the lump. 
In our series, as well as in the literature examined, 
the mean age at diagnosis is around 60 years of age.  Males 
were affected more frequently than females for which the 
reason is not clear. Incidence of an underlying autoimmune 
disorder in such patients has been reported to range from 
0% to 44%16,17. Therefore we should have a high index of 
suspicion in such patients when presenting with parotid 
lumps. A cervical lymphoadenopathy also should make 
one consider this diagnosis18. 
Most primary salivary gland lymphomas are B margi-
nal zone lymphomas arising on a background of sialadeni-
tis associated with autoimmune disorders such as Sjogrens 
syndrome. Primary T-cell lymphoma of the salivary gland 
is rare19. In our series up to five of our patients belonged 
to the follicular B cell variant and the remaining three 
were of large cell lymphoma type. However none were 
observed to be associated with autoimmune disorders. 
It was noted that autoimmune disorders affecting sa-
livary glands may predispose to uncontrolled proliferation 
of lymphatic tissue10,12,20. In these patents NHL consisted 
of a monoclonal proliferation of B-cell, which arose in 
the polyclonal infiltrates typical of benign lymphoepithe-
lial lesion that we can also find in Sjogren’s syndrome21. 
Sjogren’s syndrome is associated with 6.5 fold increase in 
the risk of NHL, 250 fold increase in the risk of parotid 
gland NHL and a dramatic 1000 fold increase in the risk 
of parotid gland MALT lymphoma. Biologically, it is well 
documented that, antigen driven immune stimulation 
develops MALT lymphoma in parotid gland in Sjögren’s 
syndrome1.
There is a difficult group of patients with or without 
Sjögren’s syndrome that develop atypical lymphoreticular 
proliferation into salivary glands. Such lesion is between 
lymphoreticular hyperplasia and neoplasia, known as 
pseudolymphoma22. This variety of lesions and histologi-
cal pictures may explicate the varied opinion that either 
doubt FNAB or frozen section and are often followed or 
substituted by superficial parotidectomy in order to reach 
the definitive diagnosis. The coexistence of Sjögren’s syn-
drome gives such patients a worse prognosis23. Survival 
period in this group of patients is generally less than three 
years. This reduction of the survival period could be due 
to both frequent systemic involvement (lacrymal, digestive, 
cutaneous localization) and the high incidence of worse 
histological type of NHL in these patients. This thought 
is confirmed on observing the survival rate of Sjogren’s 
patients with isolated low grade NHL, who have the same 
survival rate as of other patients with parotid gland NHL 
disease but without SS12,14,24. 
Warthin’s tumour and malignant lymphomas are 
only rarely assossiated. Follicular lymphoma is the most 
common lymphoma presenting as a collision tumour with 
Warthin’s25. Eventhough we had two diagnosis of Warthin’s 
in the preoperative FNAB, none were confirmed in the 
final histology. This was even when we had five follicular 
lymphomas confirmed histologically.
Freedman et al.7 noted a relationship between his-
topathology and survival26; nodular type was associated 
with prolonged survival in his series. In the present small 
group of patients survival was not related to either histo-
logical grade or pattern of lymphoma. 
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Reported rate of systemic dissemination of NHL as 
available in the current literature is variable between 30% 
to 60%3,16,27. The relative low rate of advanced stage (III-IV) 
reported in the parotid gland NHL series is contradictory 
with the general findings in NHL of other region, where 
the majority of patients have diffuse disease at the time 
of diagnosis. Our series showed the same trend of stage 
at presentation where all the patients belonged to either 
stage I or II.
Survival rate for parotid lymphoma vary conside-
rably from report to report and is generally better than 
other extranodal lymphomas in which the survival rate is 
not over 41%7. The majority of authors reported a long-
time survival rate ranging from 50% to 75%3,7,26-29. There 
is consensus between authors, regarding the grade and 
the histology of the lymphoma, that they do not appear 
to consistently modify the prognosis30. Interestingly it 
appears that, there can be a relation between the tumor 
size and survival. It was noted that if the parotid lesion 
has a diameter of less than six centimeter of diameter, the 
five years survival rate reaches 87%, on the other hand 
when the greatest diameter is more than six cm the rate 
decreases to 61%31,32. In any case, surgical reduction of 
the tumor by superficial parotidectomy is not related to 
better prognosis30.
Patients with stage I intermediate to high-grade 
NHL or stage II low-grade disease can benefit from RT 
alone8,9,28,30. The local control rate reached with RT in 
management of lymphomas is very high as reported by 
several studies33,34. In our series we obtained a complete 
local control in 87% of patients with chemotherapy and ra-
diotherapy. The fact that no palpable lesion was present in 
the follow-up is noticeable because of the strict relationship 
between tumor volume and survival as mentioned before. 
Chemotherapy is considered as an useful adjunctive 
treatment in these patients8,9 and it was used in all our 
cases. Patients with advanced stage (II or III) should be 
treated with chemotherapy if the disease is curable or if 
the patients are symptomatic. In case of low grade pattern 
or if the patients are asymptomatic, chemotherapy may be 
delayed as assessed by some authors35. 
The complication rate for patients we managed was 
relatively low with six (75%) cases of grade I mucositis 
and two (25%) cases of associated transitory dysphagia. 
The only role for surgery in these cases is as a 
diagnostic tool. We recommend, in agreement with se-
veral other authors, a superficial parotidectomy for all 
undiagnosed lumps of the gland and for unclear FNAB 
results3,18,36-39. Upon receiving a positive frozen section 
diagnosis of parotid lymphoma, the procedure should be 
stopped immediately and no further excision should be 
performed. 
CONCLUSIONS
Presence of a parotid gland swelling is a common 
presentation in the clinical practice and patients affected 
by lymphomas are clinically indistinguishable from those 
having a benign lesion. Presence of history of autoimmune 
disease and a clinically appreciable lymphoadenopathy 
in these patients should be raising the index of suspicion 
for a lymphatic malignancy. The diagnostic pathway must 
include imaging and a FNAB that may be diagnostic in 
some cases. 
Majority of the patients however, require a superfi-
cial parotidectomy to reach a definitive diagnosis, because 
both FNAB and frozen section are often inconclusive. A 
complete assessment and staging is mandatory before 
commencing therapy. Patients who present with an early 
stage or low-grade primary parotid gland NHL have a better 
prognosis. Although the number of cases in our series is 
small and the follow-up is limited, the treatment protocol 
including RT and chemotherapy showed in our series a 
good response rate with minimal recurrence risk, giving 
the physician and patients the much needed reassurance 
in its use.
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